Skip to main content
HCAT
NASDAQ Technology

Health Catalyst Reports $178M Net Loss Driven by $105M Goodwill Impairment, Announces Further Workforce Reductions and Significant Cash Burn

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
9
Price
$1.52
Mkt Cap
$126.608M
52W Low
$1.56
52W High
$5.062
Market data snapshot near publication time

summarizeSummary

Health Catalyst reported a significantly widened net loss of $178.0 million for 2025, largely due to a $105.4 million goodwill impairment. The company also experienced a sharp decline in cash, implemented further workforce reductions, and anticipates future revenue headwinds.


check_boxKey Events

  • Significant Net Loss Reported

    The company reported a net loss of $178.0 million for the year ended December 31, 2025, a substantial increase from $69.5 million in 2024.

  • Major Goodwill Impairment Charge

    A non-cash goodwill impairment charge of $105.4 million was recognized in 2025, primarily due to declines in stock price and market capitalization.

  • Substantial Decline in Cash

    Cash and cash equivalents decreased significantly from $249.6 million at the end of 2024 to $50.8 million at the end of 2025.

  • Multiple Workforce Reductions

    The company executed two additional restructuring plans in January and August 2025, reducing the global workforce by 4% and 9% respectively, following a 10% reduction in late 2023/early 2024.


auto_awesomeAnalysis

Health Catalyst, Inc. reported a substantial net loss of $178.0 million for the year ended December 31, 2025, a significant widening from the $69.5 million loss in 2024. This increased loss was primarily driven by a non-cash goodwill impairment charge of $105.4 million, indicating a re-evaluation of the value of past acquisitions and a challenging outlook. The company's cash and cash equivalents plummeted from $249.6 million in 2024 to $50.8 million in 2025, reflecting substantial cash burn. Furthermore, Health Catalyst implemented two additional workforce reductions in January and August 2025, following a prior restructuring in 2023, underscoring ongoing efforts to optimize costs amid a difficult macroeconomic environment and policy changes like the 'One Big Beautiful Bill Act' impacting Medicaid funding. These factors, combined with anticipated revenue headwinds from client migrations and churn, paint a challenging picture for the company's financial performance in the near term.

At the time of this filing, HCAT was trading at $1.52 on NASDAQ in the Technology sector, with a market capitalization of approximately $126.6M. The 52-week trading range was $1.56 to $5.06. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HCAT - Latest Insights

HCAT
Apr 27, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
HCAT
Apr 02, 2026, 5:56 PM EDT
Filing Type: 8-K
Importance Score:
7
HCAT
Mar 12, 2026, 4:58 PM EDT
Filing Type: 10-K
Importance Score:
9
HCAT
Mar 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
HCAT
Mar 12, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
HCAT
Feb 18, 2026, 1:04 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
HCAT
Feb 18, 2026, 8:59 AM EST
Filing Type: 8-K
Importance Score:
9
HCAT
Jan 23, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
HCAT
Jan 21, 2026, 8:39 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
HCAT
Jan 12, 2026, 4:26 PM EST
Filing Type: 8-K
Importance Score:
7